2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients
2018
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2018, 59: 217-225. PMID: 30427537, DOI: 10.1111/trf.15004.Peer-Reviewed Original ResearchConceptsPositive antibody screenDonor Evaluation Study-IIIAntibody screenRisk factorsRecipient EpidemiologyTransfusion historyBlood centersRBC alloantibodiesBlood donorsRed blood cell alloimmunizationCommon antibody specificitiesPrior transfusion historyRBC alloantibody formationSignificant RBC alloantibodiesHistory of transfusionAdjusted odds ratioMultivariable logistic regressionUS blood centersStudy IIIUS blood donorsPotent immune stimulusFuture medical careHealthy US blood donorsPrior transfusionsPrior pregnancyA Cluster of Cases of Babesia microti Among Neonates Traced to a Single Unit of Donor Blood
Glanternik JR, Baine IL, Rychalsky MR, Tormey CA, Shapiro ED, Baltimore RS. A Cluster of Cases of Babesia microti Among Neonates Traced to a Single Unit of Donor Blood. The Pediatric Infectious Disease Journal 2018, 37: 269-271. PMID: 28945680, DOI: 10.1097/inf.0000000000001803.Peer-Reviewed Original ResearchConceptsNeonatal intensive care unitHigh-grade parasitemiaTransfusion-transmitted babesiosisIntensive care unitCluster of casesBlood transfusionPremature infantsCare unitExchange transfusionDonor bloodInfantsBabesia microtiTransfusionBabesiosisNeonatesParasitemiaAzithromycinCliniciansAtovaquoneSingle unitBlood
2013
Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components
Xiao W, Tormey CA, Capetillo A, Maitta RW. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sanguinis 2013, 105: 334-340. PMID: 23802769, DOI: 10.1111/vox.12063.Peer-Reviewed Original ResearchConceptsAllergic transfusion reactionsTransfusion reactionsATR rateApheresis plateletsPlatelet componentsApheresis componentsAcademic medical centerABO mismatchAdverse eventsAntigen exposurePlatelet transfusionsPlatelet countDonor factorsMedical CenterApheresis productsApheresis unitsPlatelet productsStudy periodTransfusionPlateletsSimilar ratesFurther investigation
2009
Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 2009, 50: 471-477. PMID: 19804570, DOI: 10.1111/j.1537-2995.2009.02412.x.Peer-Reviewed Original ResearchConceptsSignificant adverse eventsCellular countsPatients D-dimerPlasma-exchange programPlasma removal efficiencyTherapeutic plasma exchangePrimary outcome measureFluid balance measurementsComplement cascade activationPatient's coagulationSecondary outcomesAdverse eventsPlasma exchangeAnticoagulant usageD-dimerClinical trialsFluid replacementOutcome measuresFluid balanceCoagulation systemCOBE Spectra platformFree hemoglobinStudy designWaste plasmaNew apheresis device